10 likes | 261 Views
Azmacort ® (triamcinolone acetonide) Aerosol Inhaler Kos Pharmaceuticals, Inc. Kos acquired the US marketing rights to Azmacort (both CFC and HFA) in April 2004 from Aventis Pharmaceuticals, Inc.
E N D
Azmacort®(triamcinolone acetonide)Aerosol InhalerKos Pharmaceuticals, Inc. • Kos acquired the US marketing rights to Azmacort (both CFC and HFA) in April 2004 from Aventis Pharmaceuticals, Inc. • Azmacort CFC, available commercially for over 20 years, continues to be actively prescribed by physicians. Since this product was acquired by Kos, new and total prescriptions have increased. In May 2005, combined total prescriptions were 92,000. New prescriptions accounted for nearly half of this number. • Kos is committed to conversion to HFA. Final approval for Azmacort HFA is being actively pursued by Kos, an IPACT-1 and IPACT-RS member. In a December 2004 meeting with FDA, further development and approval plans for this product were discussed. Commercialization is anticipated in approximately 2008. • Other Kos aerosol R & D projects are also underway. Four projects, including two for asthma/COPD, one undisclosed for a systemic disease, and the last for inhaled insulin, are at various stages of development.